Biblioteca Virtual em Saúde

Pesquisa | Influenza A (H1N1)

  • BIREME | OPAS | OMS logo
 

Histórico de pesquisa  ()

Sua seleção  ()

 0 documento(s) selecionado(s).

Refine sua pesquisa

Collapse All  Ocultar
Expand All  Mostrar
Áreas temáticas
Texto completo (877)
Idioma
Ano de publicação

Enviar por email

Você tem 0 documento(s) selecionado(s).

Nenhum documento selecionado

 
Resultados  1-12 de 1.154
1.

Surveillance of antiviral resistance markers in Argentina: detection of E119V neuraminidase mutation in a post-treatment immunocompromised patient

Autor(es): Pontoriero, Andrea; Avaro, Martín; Benedetti, Estefania; Russo, Mara; Czech, Andrea; Periolo, Natalia; Campos, Ana; Zamora, Ana; Baumeister, Elsa
Fonte: Mem. Inst. Oswaldo Cruz;111(12): 745-749, Dec. 2016. graf
LILACS - Literatura Latino-Americana e do Caribe em Ciências da Saúde ID: 829259
Resumo: Although vaccines are the best means of protection against influenza, neuraminidase inhibitors are currently the main antiviral treatment available to control severe influenza cases. One of the most frequent substitutions in the neuraminidase (NA) protein of influenza A(H3N2) viruses during or soon after oseltamivir administration is E119V mutation. We describe the emergence of a mixed viral population with the E119E/V mutation in the NA protein sequence in a post-treatment influenza sample (mais)
2.

Design, synthesis, and in vitro biological evaluation of novel 6-methyl-7-substituted-7-deaza purine nucleoside analogs as anti-influenza A agents.

Autor(es): Lin, Cai; Sun, Chenghai; Liu, Xiao; Zhou, Yiqian; Hussain, Muzammal; Wan, Junting; Li, Minke; Li, Xue; Jin, Ruiliang; Tu, Zhengchao; Zhang, Jiancun
Fonte: Antiviral Res;129: 13-20, 2016 May.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 26802557
Resumo: Among many subtypes of influenza A viruses, influenza A(H1N1) and A(H3N2) subtypes are currently circulating among humans (WHO report 2014-15). Therapeutically, the emergence of viral resistance to currently available drugs (adamantanes and neuraminidase inhibitors) has heightened alarms for developing novel drugs that could address diverse targets in the viral replication cycle in order to improve treatment outcomes. To this regard, the design and synthesis of nucleoside analog inhibitors (mais)
4.

A Balance between Inhibitor Binding and Substrate Processing Confers Influenza Drug Resistance.

Autor(es): Jiang, Li; Liu, Ping; Bank, Claudia; Renzette, Nicholas; Prachanronarong, Kristina; Yilmaz, Lutfu S; Caffrey, Daniel R; Zeldovich, Konstantin B; Schiffer, Celia A; Kowalik, Timothy F; Jensen, Jeffrey D; Finberg, Robert W; Wang, Jennifer P; Bolon, Daniel N A
Fonte: J Mol Biol;428(3): 538-553, 2016 Feb 13.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 26656922
Resumo: The therapeutic benefits of the neuraminidase (NA) inhibitor oseltamivir are dampened by the emergence of drug resistance mutations in influenza A virus (IAV). To investigate the mechanistic features that underlie resistance, we developed an approach to quantify the effects of all possible single-nucleotide substitutions introduced into important regions of NA. We determined the experimental fitness effects of 450 nucleotide mutations encoding positions both surrounding the active site and (mais)
5.

Detection of Rare Drug Resistance Mutations by Digital PCR in a Human Influenza A Virus Model System and Clinical Samples.

Autor(es): Whale, Alexandra S; Bushell, Claire A; Grant, Paul R; Cowen, Simon; Gutierrez-Aguirre, Ion; O'Sullivan, Denise M; Zel, Jana; Milavec, Mojca; Foy, Carole A; Nastouli, Eleni; Garson, Jeremy A; Huggett, Jim F
Fonte: J Clin Microbiol;54(2): 392-400, 2016 Feb.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 26659206
Resumo: Digital PCR (dPCR) is being increasingly used for the quantification of sequence variations, including single nucleotide polymorphisms (SNPs), due to its high accuracy and precision in comparison with techniques such as quantitative PCR (qPCR) and melt curve analysis. To develop and evaluate dPCR for SNP detection using DNA, RNA, and clinical samples, an influenza virus model of resistance to oseltamivir (Tamiflu) was used. First, this study was able to recognize and reduce off-target ampli (mais)
6.

NAIplot: An opensource web tool to visualize neuraminidase inhibitor (NAI) phenotypic susceptibility results using kernel density plots.

Autor(es): Lytras, Theodore; Kossyvakis, Athanasios; Mentis, Andreas
Fonte: Antiviral Res;126: 18-20, 2016 Feb.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 26692213
Resumo: The results of neuraminidase inhibitor (NAI) enzyme inhibition assays are commonly expressed as 50% inhibitory concentration (IC50) fold-change values and presented graphically in box plots (box-and-whisker plots). An alternative and more informative type of graph is the kernel density plot, which we propose should be the preferred one for this purpose. In this paper we discuss the limitations of box plots and the advantages of the kernel density plot, and we present NAIplot, an opensource (mais)
7.

Pharmacophore-Based Virtual Screening for Identification of Novel Neuraminidase Inhibitors and Verification of Inhibitory Activity by Molecular Docking.

Autor(es): Batool, Sidra; Mushtaq, Gohar; Kamal, Warda; Kamal, Mohammad A
Fonte: Med Chem;12(1): 63-73, 2016.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 26152143
Resumo: Oseltamivir and Zanamivir are two of the recently licensed neuraminidase inhibitors used for the treatment of influenza. However, alternative antiviral agents are needed due to the development of resistant mutations in Oseltamivir subtype H1N1 and H5N1 avian influenza A viruses, the latter being a highly pathogenic avian virus that can be transferred to humans upon immediate contact with H5N1 infected poultry or surface. Novel drug inhibiting group 1 neuraminidases may potentially be develo (mais)
8.

The effect of intravenous peramivir, compared with oral oseltamivir, on the outcome of post-influenza pneumococcal pneumonia in mice.

Autor(es): Tanaka, Akitaka; Nakamura, Shigeki; Seki, Masafumi; Iwanaga, Naoki; Kajihara, Toshiki; Kitano, Mitsutaka; Homma, Tomoyuki; Kurihara, Shintaro; Imamura, Yoshifumi; Miyazaki, Taiga; Izumikawa, Koichi; Kakeya, Hiroshi; Yanagihara, Katsunori; Kohno, Shigeru
Fonte: Antivir Ther;20(1): 11-9, 2015.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 24517996
Resumo: BACKGROUND: Pneumococcal pneumonia often occurs secondary to influenza infection and accounts for a large proportion of the morbidity and mortality associated with seasonal and pandemic influenza outbreaks. Peramivir is a novel, intravenous neuraminidase inhibitor that exhibits potent antiviral activity against influenza A and B viruses. We investigated the efficacy of peramivir for modulating the severity of secondary pneumococcal pneumonia. METHODS: CBA/JNCrlj mice, infected with influenz (mais)
9.

Comparison between virus shedding and fever duration after treating children with pandemic A H1N1/09 and children with A H3N2 with a neuraminidase inhibitor.

Autor(es): Sugaya, Norio; Sakai-Tagawa, Yuko; Bamba, Masahiro; Yasuhara, Rieko; Yamazaki, Masahiko; Kawakami, Chiharu; Yamaguchi, Yoshio; Ide, Yoshiaki; Ichikawa, Masataka; Mitamura, Keiko; Kawaoka, Yoshihiro
Fonte: Antivir Ther;20(1): 49-55, 2015.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 24832015
Resumo: BACKGROUND: Shedding of the pandemic virus during an influenza pandemic is thought to persist longer than shedding of influenza viruses during annual influenza seasons, because people have much less immunity against a pandemic influenza. A correlation is thought to exist between the length of virus shedding and the clinical severity of influenza illness. METHODS: We compared the virus isolation rates of children with pandemic A H1N1/09 influenza infection and children with A H3N2 influenza (mais)
10.

The effects of neuraminidase inhibitors on the release of oseltamivir-sensitive and oseltamivir-resistant influenza viruses from primary cultures of human tracheal epithelium.

Autor(es): Yamaya, Mutsuo; Nadine, Lusamba; Kubo, Hiroshi; Saito, Kousuke; Saito, Reiko; Nishimura, Hidekazu
Fonte: J Med Virol;87(1): 25-34, 2015 Jan.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 24838828
Resumo: Defining the effects of neuraminidase inhibitors on influenza virus infection may provide important information for the treatment of patients. The effects of neuraminidase inhibitors have been examined using various methods, including viral release from kidney cells. However, the effects of neuraminidase inhibitors on viral release from primary cultures of human tracheal epithelial cells, which retain functions of the original tissues, have not been studied. The effects of neuraminidase inh (mais)
11.

A randomized study of standard versus double dose oseltamivir for treating influenza in the community.

Autor(es): Dixit, Rashmi; Khandaker, Gulam; Hay, Peter; McPhie, Kenneth; Taylor, Janette; Rashid, Harunor; Heron, Leon; Dwyer, Dominic; Booy, Robert
Fonte: Antivir Ther;20(7): 689-98, 2015.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 24912485
Resumo: BACKGROUND: The neuraminidase inhibitors are the treatment of choice for influenza virus infection. Oseltamivir-resistant (OsR) strains of influenza A(H1N1)pdm09 are described, but the effect of higher dose oseltamivir on efficacy, safety and emergence of resistance has not been addressed in the developed setting in outpatients. The objectives of the study were to compare standard dose (SD) versus double dose (DD) oseltamivir regimens for frequency of detecting OsR influenza virus, clinical (mais)
Resultados  1-12 de 1.154